On February 4, 2015, Patients for Biologics Safety & Access (PBSA) sent letters to Congress urging the Senate HELP and House Energy & Commerce committees to convene oversight hearings on biosimilars. PBSA members seek assurance that patient safety is being fully protected as FDA implements the Biologics Price Competition and Innovation Act (BPCIA).  
 
The letter states, “Given the importance of this issue to patient safety and the impending actions by the FDA to develop biosimilar approval standards, we urge Congress to schedule the first oversight hearings before the committees soon and ensure patient voices are represented at such hearings.”

 

Comment